AlphaStocks
6.6
Consider Buy

GILEAD SCIENCES, INC. (GILD)

Health Care / Biotechnology

S&P 500

$133.51

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#129out of 1126 in Health Care

Is GILEAD SCIENCES, INC. a Good Investment in 2026?

GILEAD SCIENCES, INC. (GILD) scores 6.6 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates GILEAD SCIENCES, INC. as Strong (7/9). However, the Graham model rates it Caution — Significantly above fair value. GILEAD SCIENCES, INC. currently trades below its estimated fair value of $190, suggesting potential upside. GILEAD SCIENCES, INC. ranks #129 out of 1126 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E19.7ROE38.5Market Cap166BDiv Yield2.4

Estimated Fair Value

$190.0130% below

Fair value above market price. EPS grew 1673% year-over-year. ROE of 38% signals strong profitability. P/E of 20x is moderate for this quality level.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Attractive

Top 25% (rank 11%)

Frequently Asked Questions

Is GILEAD SCIENCES, INC. (GILD) a good investment?
Based on AlphaStocks' composite analysis, GILEAD SCIENCES, INC. (GILD) scores 6.6 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Fair value above market price. EPS grew 1673% year-over-year. ROE of 38% signals strong profitability. P/E of 20x is moderate for this quality level.
What is GILEAD SCIENCES, INC.'s Piotroski F-Score?
GILEAD SCIENCES, INC.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is GILD overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $190, GILD appears undervalued. The stock currently trades 30% below its estimated fair value. Fair value above market price. EPS grew 1673% year-over-year. ROE of 38% signals strong profitability. P/E of 20x is moderate for this quality level.
How does GILD compare to other Health Care stocks?
GILEAD SCIENCES, INC. ranks #129 out of 1126 stocks in the Health Care sector, placing it in the top 11% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about GILD?
AlphaStocks evaluates GILD using five proven investment models. Piotroski: Strong; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.6/10.

Similar Stocks

FTIPARRAZN

Compare GILD with

GILD vs FTIGILD vs PARRGILD vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer